0.05Open0.05Pre Close1 Volume309 Open Interest2.50Strike Price5.00Turnover1957.01%IV136.11%PremiumOct 18, 2024Expiry Date0.00Intrinsic Value100Multiplier0DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.1721Delta0.3587Gamma21.60Leverage Ratio-0.2163Theta0.0000Rho3.72Eff Leverage0.0001Vega
Equillium Stock Discussion
is this stock still even alive
$Equillium (EQ.US)$
Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company, recently announced promising topline results from its Phase 2 proof-of-concept (PoC) study of EQ101 in adult patients suffering from moderate, severe, or very-severe alopecia areata (AA). This autoimmune condition, driven by an immune cell attack on hair follicles, leads...
Equillium Announces Positive Topline Data From Phase 2 Study of EQ101 in Alopecia Areata
Equillium Inc: EQ101 Was Well Tolerated in Subjects With Alopecia Areata With No Serious Adverse Events Reported
No comment yet